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A novel nurse-delivered multicomponent intervention for major depressive disorder (MDD) in cancer outpatients was compared
with usual care alone in a nonrandomised matched group design (n¼30 per group). At the final 6-month outcome, 38.5% (95% CI,
5.4–57%) fewer patients in the intervention group still met the criteria for MDD.
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Major depressive disorder (MDD) (American Psychiatric Associa-
tion, 1994) is associated with an increased symptom burden,
greater disability, reduced quality of life and poorer medical
outcome (Katon, 1996), and occurs in a substantial proportion of
cancer patients (Lynch, 1995; McDaniel et al, 1995). There is some
evidence for the efficacy of antidepressant drugs (McDaniel et al,
1995) and for psychological therapies (Sheard and Maguire, 1999).
However, many patients do not receive any potentially effective
treatment (Lynch, 1995). We have therefore developed and piloted
a cancer nurse-delivered intervention. The aim of this study was to
perform a preliminary evaluation of its feasibility and efficacy in
oncology outpatients.
MATERIALS AND METHODS
Patients and recruitment
We recruited patients with MDD from consecutive attenders at
breast, gynaecological, bladder, prostate, testicular and colorectal
clinics at the Edinburgh Cancer Centre between September 1999
and September 2000 using a screening procedure described in the
companion paper (Sharpe et al, 2003).
Patients were excluded if: (a) the oncologist predicted that they
would not survive to follow-up or if they had (b) a complicating
and uncontrolled medical problem, (c) a complicating major
psychiatric diagnosis, (d) a history of continuous depression for
more than 1 year prior to cancer diagnosis, (e) difficulty in
communicating and (f) were currently receiving active specialist
treatment from a psychologist or psychiatrist. When patients were
excluded, their doctors were told of their diagnosis of MDD.
Design and power
The study was a nonrandomised comparison of the outcome of
two sequentially recruited cohorts. To detect a difference in the
proportions of patients still meeting the criteria for MDD of the
magnitude size previously reported in a similar study in primary-
care patients (35%) (Katon et al, 1996) using a paired analysis,
approximately 56 cases (28 in each of the treatment and usual care
groups) are required (80% power and significance level of 0.05).
MEASURES
Baseline measures
Demographic and cancer data: These were collected from medical
records.
Structured Clinical Interview for DSM-IV (SCID) The presence of
MDD and depressive symptoms was determined during telephone
interview using the SCID (First et al, 1999). All symptoms counted
toward the diagnosis and no judgements were made about their
aetiology. Telephone SCID has good agreement with a face-to-face
interview (Cacciola et al, 1999), and is acceptable to patients (Allen
et al, 2003).
Hospital Anxiety and Depression Scale (HADS) (Zigmond and
Snaith, 1983): Anxiety and depressive symptoms were assessed
with this 14-item self-rated scale designed for use in the medically
ill (see companion paper Sharpe et al, 2003).
Manchester Concerns Checklist (Harrison et al, 1994): Patient’s
concerns were rated using this 14-item checklist, each concern
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lbeing rated on a five-point scale from ‘not a worry’ to ‘extremely
worried’.
Outcome measures The primary outcome measure was the
presence of MDD according to DSM-IV criteria as assessed by
the SCID interview and determined from audiotapes and/or notes
of the interviews by a consultant psychiatrist (MS) blind to the
patient’s treatment status. The number of MDD symptoms on the
SCID and self-rated scales listed above were secondary outcome
measures.
Definition of adequate dose of antidepressant drugs We defined
the adequacy of the dose of antidepressant drugs as that specified
in the British National Formulary (www.bnf.org), but accepting
75mg as effective for tricyclic antidepressants (Furukawa et al,
2002).
Treatment conditions
Usual care alone We told the GP, oncologist and the patient
about the diagnosis of MDD and the GP was asked to ‘manage the
patient as they normally would’.
Usual care plus the experimental intervention These patients also
received the nurse-delivered intervention, which comprised:
(1) Education about depression (e.g. that the symptoms of
depression were a separate problem from the cancer and of
the probable effectiveness of treatment).
(2) Up to ten 30-min sessions of problem-solving therapy
intended to help patients to take a positive and systematic
approach to tackling their problems (Wood and Mynors-
Wallis, 1997).
(3) Patients were encouraged, within the context of problem
solving, to consider seeing their GP to discuss antidepressant
therapy. Although prescribing was left to the GP, the nurse
ensured that if taken, a therapeutic dose of antidepressant was
attained and adhered to.
(4) Coordinating and monitoring the patient’s treatment with
respect to the MDD.
The cancer nurse received 6 months training in the intervention
and was rated as competent on the basis of videotape recordings of
treatment. She received weekly supervision from a consultant
psychiatrist during the trial. Treatment sessions took place weekly
in the hospital or where necessary at home or by telephone. After
treatment, patients were told that they could contact the nurse for
‘booster’ sessions.
Procedure
All participating patients gave written consent.
Allocation to treatment We assigned patients recruited between
1999 and February 2000 to usual care only and those recruited
from March 2000 to August 2000 to the additional intervention.
Follow-up Outcome assessments were at 3 and 6 months by
telephone interview and postal self-report questionnaires. At the
end of the study period, GPs were notified if their patient still had
MDD.
Statistical analysis
Matching of the groups was by individual baseline variables in the
following order: sex, age (10-year bands), presence of active
disease and cancer site. The statistical analysis was appropriate for
matched pairs. The McNemar test was used to compare propor-
tions and paired t-tests to compare means. All tests were two-
tailed.
Ethical approval
Lothian Research Ethics Committee approved the study.
RESULTS
Patients and recruitment
We identified 196 patients with MDD by screening. Seven refused
further assessment and 39 were ineligible (20 because of chronic
depression and 19 for other reasons). Nonparticipation among
those approached was 31of 83 (37%) for usual care and 34 of 64
(53%) for the additional intervention. The reasons given were time,
distance and a preference not to discuss emotional matters. The
participating clinicians were positive about the intervention.
Matching of groups
After matching 30 usual care only patients to the 30 receiving the
intervention, there were no substantial or statistically significant
differences between groups on demographic, cancer or psycholo-
gical variables (see Tables 1 and 2). Most had breast cancer and
were in a postacute treatment phase. A greater number of patients
in the intervention group had received antidepressant drugs prior
to recruitment, but only a very small and similar number were
taking a therapeutic dose.
Missing outcome data
Data on the principal outcome was available on 28 pairs at 3
months and 26 pairs at 6 months (four patients died and two were
lost to follow-up). There was a small amount of additional missing
data on secondary measures due to noncompletion of question-
naires.
Intervention received
Problem-solving therapy Every patient in the intervention group
had an initial assessment, plus between 1 and 13 weekly problem-
solving sessions (mean 7.3, s.d. 2.0) of approximately 30min
duration. The duration of treatment ranged from 2 to 16 weeks.
Only six patients requested post-treatment ‘booster’ sessions. Only
four sessions were conducted at the patients’ home and very few by
telephone. The treating nurse spent a mean of 6h with each patient
and an additional 4h on administration, calls to GPs, travel and
supervision. The psychiatrist provided 1h of supervision per week
and attended treatment sessions on four occasions. The total time
spent per patient treated was therefore approximately 10h for the
nurse and 1h for the psychiatrist.
Antidepressant medication During the 6-month study period,
most (27 of 30; 90%) of the patients in the intervention group were
prescribed an antidepressant by their GP, although only 16 (53%)
attained a therapeutic dose, largely because of the poor tolerance
of side effects. In comparison, only half (16 of 30; 53%) of the
patients in the usual care only group were prescribed an
antidepressant drug and only (23%) attained a therapeutic dose.
Other treatments received
One patient in the treatment group and four patients in the usual
care only group saw a psychologist or psychiatrist during the study
period. A small number of patients in each group saw other
counsellors.
Management of major depression
M Sharpe et al
311
British Journal of Cancer (2004) 90(2), 310–313 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lOutcome data
Principal outcome Table 2 shows the percentage of patients
who no longer met the criteria for MDD at 3 and 6 months and
the number of symptoms of MDD elicited on the SCID
interview. There was a substantially and statistically significantly
greater improvement in the intervention group at both time
points.
Secondary outcomes Table 2 also shows the substantial and
statistically significantly greater reductions in the self-rated
secondary outcomes, which were greatest at 3 months and largely
but not entirely maintained at 6 months.
DISCUSSION
Main findings
This preliminary comparison of the nurse-delivered intervention
with usual care suggests that it is feasible to train a nurse, to
deliver the intervention (although with a high patient refusal
rate – see below) and to gain the cooperation of clinicians. It
also produces a substantially better outcome for patients. The
beneficial effect is apparent at the end of the active treatment phase
(3 months) and is largely maintained at the follow-up point (6
months).
Limitations
Nonrandomised comparisons can overestimate the differences
between treatments (Altman and Bland, 1999). There was a
relatively low participation rate, although surprisingly, this was not
much higher in those offered usual care only than in those asked to
participate in the much more time-consuming treatment inter-
vention. The main reason for this is probably that patients were
recruited by screening rather than referral. An intervention study
for depression after myocardial infarction reported similar
findings (Frasure-Smith et al, 1997). Participants were predomi-
nantly females with inactive breast cancer, limiting the generali-
sability of the findings. The sample was small leading to wide
confidence intervals around the results. Finally, as a single nurse
administered the intervention, we cannot conclude that cancer
nurses in general could necessarily be trained to deliver the
treatment effectively.
Other studies
Oncologists miss many cases of depression (Fallowfield et al,
2001). However, simply feeding back the findings of screening
does not seem to help (McLachlan et al, 2001). We therefore
need to not only improve the identification of depression
but also the provision of treatment. Specialist psychiatrists and
psychologists are in short supply. One potential solution that
requires further evaluation is for the medical and nursing
oncology staff to play a greater role (Stiefel et al, 2001). It is
therefore surprising that there have been few trials of cancer
nurse delivered interventions for depression. Early studies
found that simple counselling by specialist nurses did not
prevent depression, but that better recognition and subsequent
treatment by a psychiatrist improved outcome (Maguire
et al, 1980; Maguire et al, 1985). We are not aware of any
previous studies of the management of established MDD
comorbid with cancer by oncology nurses or other oncology
clinic staff.
Implications
The results of this preliminary study indicate that depression
management systems that combine screening and intervention are
worthy of further development and evaluation in randomised
trials.
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Table 1 Demographic and characteristics of depression of the matched
groups at baseline
Number (percentage) unless
otherwise specified
Intervention
(n¼30)
Usual care
(n¼30)
Demographics
Mean age in years (standard
deviation)
58 (10.6) 56 (10.5)
Female 28 (93.3) 28 (93.3)
Depression
Median duration (months) of
episode (range)
7 (1–120) 7 (1–96)
Depression onset in relation to
cancer
With diagnosis 7 (23.3) 10 (33.3)
With recurrence 3 (10) 2 (6.7)
After diagnosis/recurrence 20 (66.7) 18 (60)
Self reported previous depression
No previous episodes 15 (50) 17 (56.7)
Prescribed antidepressant agent
for this episode
15 (50) 5 (16.7)
Currently taking a therapeutic
dose of an antidepressant agent
a
5 (16.7) 3 (10)
Previously received
psychological therapy
b
5 (16.7) 1 (3.3)
Previously used other support
services
c
3 (10) 3 (10)
Cancer
Median time (years) since diagnosis
(range)
4 (0–19) 3 (0–29)
Site
Breast
d 26 (87) 27 (90)
Disease state
No active disease 24 (80) 24 (80)
Local disease 2 (7) 2 (7)
Metastases 4 (13) 4 (13)
Treatment stage
Active treatment
e 8 (27) 2 (7)
aDefined in methods.
bConsulted a psychiatrist/psychologist.
cOther supportive
services – breast care nurse, occupational health-care nurse, counsellor, faith-healer
and non-NHS charitably funded cancer support centre.
dOther sites were the
bladder, prostate, colorectal, thyroid and ovary.
eLong-term hormonal-based
therapies such as tamoxifen not included as active treatment.
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Table 2 Primary and secondary outcome variables at baseline 3 and 6 months
Time No. pairs Intervention Usual care only Mean difference (95% CI) t Sig. (P-value)
Interview (SCID)
No MDD*
Baseline 30 0 0
3 months 28 71 (20) 32 (9) 39.3 (7.9–56) 0.01
6 months 26 81 (22) 42 (11) 38.5 (5.4–57) 0.02
Number of MDD symptoms
Baseline 30 6.4 (1.2) 6.5 (1.3) 0 ( 0.7–0.5) 0.3 0.74
3 months 28 3.1 (2.4) 5.5 (2.2) 2.3 ( 3.6– 1.1) 3.8 0.001
6 months 26 2.6 (2.3) 4.9 (2.2) 2.2 ( 3.8– –0.7) 3.0 0.006
Self-Rated Scales
HADS anxiety
Baseline 30 12.9 (3.1) 12.8 (3.6) 0 ( 1.9–2.0) 0.04 0.97
3 months 27 7.7 (4.1) 12.6 (3.6) 4.8 ( 7.1– 2.6) 4.3 0.000
6 months 26 7.9 (4.7) 11.7 (3.7) 3.8 ( 6.6– 0.9) 2.7 0.012
HADS depression
Baseline 30 10.4 (3.6) 10.3 (4.0) 0 ( 1.8–2.0) 0.71 0.94
3 months 27 7.0 (4.4) 10.6 (3.7) 3.5 ( 5.9– 1.1) 3.02 0.006
6 months 26 7.0 (4.1) 9.6 (4.7) 2.7 ( 5.5–0.1) 1.96 0.061
Number of concerns
Baseline 30 6.7 (3.5) 6.7 (3.1) 0 ( 1.7–1.6) 0.04 0.97
3 months 28 3.9 (4.1) 6.0 (3.7) 2.4 ( 4.5– 0.2) 2.3 0.03
6 months 25 3.3 (3.9) 5.7 (4.1) 2.2 ( 4.7–0.34) 1.8 0.09
Outcomes expressed as percentages and percentage differences for pairs, and means and mean differences for pairs, with confidence intervals. Statistical significance by paired t-
tests and McNemar test*.
[2]All means and (s.d.) except*, which are percentages (numbers). CI¼confidence intervals; SCID¼Structured Clinical Interview for DSM-IV;
MDD¼major depressive disorder; HADS¼Hospital Anxiety and Depression Scale.
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